Roche has launched its DISCOVERY 5-Plex procedure and reagents to be used for immunohistochemistry (IHC) research applications.
The pre-optimised, fully automated multiplex procedure is applicable on the VENTANA DISCOVERY ULTRA2 instrument.
Roche's DISCOVERY product line is a research-use-only (RUO) portfolio of instruments and reagents for research in immunohistochemistry (IHC) and in situ hybridisation (ISH).
A part of the Discovery product portfolio, the DISCOVERY ULTRA research instrument is designed to fully automate single or multiplex IHC and ISH applications and a growing line of reagents for full automation designed to meet the needs of the research community.
The DISCOVERY 5-Plex procedure enables the researchers to investigate up to five biomarkers on a single slide, preserving tissue and maximising data.
It facilitates the researchers with a pre-optimised workflow to simplify the staining process. The ready-to-use detection reagents offers crisp, specific signals and distinct information about protein co-expression patterns.
Roche Tissue Diagnostics head Ann Costello said: "To better investigate the complexities of cancer biology and possible treatment strategies, it is increasingly important to detect multiple biomarkers on a single slide.
"The launch of the innovative DISCOVERY 5-Plex procedure advances automation in multiplexing technology, which is expected to play a critical role in cancer research in the future."
The launch of the DISCOVERY 5-Plex procedure will be followed by the commercial launch of the DISCOVERY FAM Kit, DISCOVERY Rhodamine 6G Kit, DISCOVERY Red 610 Kit, and DISCOVERY DCC Kit.
